MX2011013078A - Nuevos compuestos potentes antisentido anti apolipoproteina b (apob). - Google Patents

Nuevos compuestos potentes antisentido anti apolipoproteina b (apob).

Info

Publication number
MX2011013078A
MX2011013078A MX2011013078A MX2011013078A MX2011013078A MX 2011013078 A MX2011013078 A MX 2011013078A MX 2011013078 A MX2011013078 A MX 2011013078A MX 2011013078 A MX2011013078 A MX 2011013078A MX 2011013078 A MX2011013078 A MX 2011013078A
Authority
MX
Mexico
Prior art keywords
apo
antisense compounds
potent anti
hypercholesterolemia
new potent
Prior art date
Application number
MX2011013078A
Other languages
English (en)
Inventor
Ellen Marie Straarup
Niels Fisker Nielsen
Marie Lindholm
Original Assignee
Santaris Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2009/067561 external-priority patent/WO2010076248A1/en
Application filed by Santaris Pharma As filed Critical Santaris Pharma As
Publication of MX2011013078A publication Critical patent/MX2011013078A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA

Abstract

La presente invención se refiere a compuestos de oligómero (oligómeros), que activan ARNm APO-B100 en una célula, conduciendo a la expresión reducida de APO-B100. La reducción de la expresión de APO-B100 es benéfica para el tratamiento de ciertos trastornos médicos, tales como enfermedades asociadas con la actividad de apolipoproteína B, tal como en un ejemplo no limitante, diferentes tipos de desequilibrio en colesterol HDL/LDL; dislipidemias, por ejemplo, hiperlipidemia familiar combinada (FCHL), hiperlipidemia ui hipercolesterolemia, hipercolesterolemia resistente a estatina; enfermedad de arteria coronaria (CAD), enfermedad cardíaca coronaria (CHD), ateroesclerosis.
MX2011013078A 2009-06-12 2010-06-14 Nuevos compuestos potentes antisentido anti apolipoproteina b (apob). MX2011013078A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18638809P 2009-06-12 2009-06-12
US25309009P 2009-10-20 2009-10-20
PCT/EP2009/067561 WO2010076248A1 (en) 2008-12-31 2009-12-18 Use of lna apob antisense oligomers for the treatment of acute coronary syndromes
PCT/EP2010/058278 WO2010142805A1 (en) 2009-06-12 2010-06-14 New potent anti apob antisense compounds

Publications (1)

Publication Number Publication Date
MX2011013078A true MX2011013078A (es) 2012-02-01

Family

ID=42541569

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011013078A MX2011013078A (es) 2009-06-12 2010-06-14 Nuevos compuestos potentes antisentido anti apolipoproteina b (apob).

Country Status (12)

Country Link
US (1) US9290758B2 (es)
EP (1) EP2440215B1 (es)
JP (1) JP2012529279A (es)
CN (1) CN102802637A (es)
AU (1) AU2010258570B2 (es)
BR (1) BR112012000214A2 (es)
CA (1) CA2764822A1 (es)
ES (1) ES2555057T3 (es)
IL (1) IL216519A0 (es)
MX (1) MX2011013078A (es)
NZ (1) NZ596608A (es)
WO (1) WO2010142805A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2018112970A (ru) 2012-11-15 2019-03-01 Рош Инновейшен Сентер Копенгаген А/С Конъюгаты олигонуклеотидов
MY177989A (en) 2013-01-30 2020-09-28 Hoffmann La Roche Lna oligonucleotide carbohydrate conjugates
DK3013959T3 (da) 2013-06-27 2020-02-17 Roche Innovation Ct Copenhagen As Antisense-oligomerer og konjugater målrettet pcsk9
RU2016122168A (ru) * 2013-11-14 2017-12-19 Рош Инновейшен Сентер Копенгаген А/С Антисмысловые конъюгаты, направленные на аполипопротеин b
CA3091789A1 (en) * 2018-02-21 2019-08-29 Bristol-Myers Squibb Company Camk2d antisense oligonucleotides and uses thereof
JP2022506958A (ja) * 2018-11-13 2022-01-17 レグルス セラピューティクス インコーポレイテッド Ｍｉｒ－１０ｂ活性を調節するためのマイクロｒｎａ化合物及び方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962029A (en) 1987-10-02 1990-10-09 Cetus Corporation Covalent oligonucleotide-horseradish peroxidase conjugate
US4914210A (en) 1987-10-02 1990-04-03 Cetus Corporation Oligonucleotide functionalizing reagents
US6617442B1 (en) 1999-09-30 2003-09-09 Isis Pharmaceuticals, Inc. Human Rnase H1 and oligonucleotide compositions thereof
US7407943B2 (en) * 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
WO2004009151A2 (en) * 2002-07-19 2004-01-29 Medela Holding Ag Breast pump connector device
US7087229B2 (en) 2003-05-30 2006-08-08 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
DK2752488T3 (da) 2002-11-18 2020-04-20 Roche Innovation Ct Copenhagen As Antisense-design
US8110674B2 (en) * 2003-03-07 2012-02-07 Alnylam Pharmaceuticals, Inc. Therapeutic compositions
CA2521464C (en) 2003-04-09 2013-02-05 Alnylam Pharmaceuticals, Inc. Irna conjugates
JP4912873B2 (ja) * 2003-04-09 2012-04-11 アルナイラム ファーマシューティカルズ， インコーポレイテッド ｉＲＮＡ複合体
EP1828219A4 (en) 2004-11-17 2008-07-23 Protiva Biotherapeutics Inc ARNSI SILENCE OF APOLIPOPROTEIN B
US20090118213A1 (en) * 2005-09-15 2009-05-07 Henrik Frydenlund Hansen Rna antagonist compounds for the inhibition of apo-b100 expression
WO2007031091A2 (en) 2005-09-15 2007-03-22 Santaris Pharma A/S Rna antagonist compounds for the modulation of p21 ras expression
CN102766630B (zh) 2006-01-27 2014-05-07 Isis制药公司 6-修饰的双环核酸类似物
DK2002004T3 (en) 2006-03-23 2015-11-30 Roche Innovation Ct Copenhagen As LITTLE INTERNAL SEGMENTED INTERFERENCE RNA
ES2389737T3 (es) 2006-05-11 2012-10-31 Isis Pharmaceuticals, Inc. Análogos de ácidos nucleicos bicíclicos modificados en 5'
CA2662520A1 (en) 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Polymeric conjugates containing positively-charged moieties
AU2007296054B2 (en) 2006-09-15 2013-03-28 Enzon Pharmaceuticals, Inc. Hindered ester-based biodegradable linkers for oligonucleotide delivery
EP2090127A2 (en) 2006-10-30 2009-08-19 Nokia Corporation Method, apparatus and system providing operator controlled mobility for user equipment
WO2008113830A1 (en) 2007-03-22 2008-09-25 Santaris Pharma A/S Rna antagonist compounds for the inhibition of apo-b100 expression
AU2008260277C1 (en) 2007-05-30 2014-04-17 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
EP2173760B2 (en) 2007-06-08 2015-11-04 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
ES2376507T5 (es) 2007-07-05 2015-08-31 Isis Pharmaceuticals, Inc. Análogos de ácidos nucleicos bicíclicos 6-disustituidos
WO2009067647A1 (en) 2007-11-21 2009-05-28 Isis Pharmaceuticals, Inc. Carbocyclic alpha-l-bicyclic nucleic acid analogs

Also Published As

Publication number Publication date
AU2010258570B2 (en) 2016-09-01
ES2555057T3 (es) 2015-12-28
EP2440215B1 (en) 2015-10-21
JP2012529279A (ja) 2012-11-22
IL216519A0 (en) 2012-02-29
WO2010142805A1 (en) 2010-12-16
EP2440215A1 (en) 2012-04-18
WO2010142805A4 (en) 2011-03-03
NZ596608A (en) 2014-01-31
CA2764822A1 (en) 2010-12-16
US9290758B2 (en) 2016-03-22
AU2010258570A1 (en) 2011-12-15
US20120115936A1 (en) 2012-05-10
CN102802637A (zh) 2012-11-28
BR112012000214A2 (pt) 2018-06-19

Similar Documents

Publication Publication Date Title
MX2011013078A (es) Nuevos compuestos potentes antisentido anti apolipoproteina b (apob).
FR22C1062I2 (fr) Thérapie de remplacement enzymatique d'escalade de doses pour le traitement du déficit en sphingomyélinase acide
TR201909777T4 (tr) Sübsti̇tüe ki̇nazoli̇nonlara yöneli̇k oral çabuk salimli formülasyonlar
MX2011012409A (es) Metodos y composiciones de endoxifeno en el tratamiento de enfermedades mamiferas.
WO2013074974A3 (en) Modified rnai agents
EP2192911B8 (de) Pflanzenextrakt aus thc-armen cannabis zur behandlung von erkrankungen
ZA201208535B (en) Formulations of quinones for the treatment of ophthalmic diseases
BR112013024122A2 (pt) compostos de benzoxazepina seletivos para p110 delta pi3k e métodos de uso
MX2013009191A (es) Oligonucleotidos antisentido.
CR11272A (es) Enzimas de aciltranferasa de lecitina-colesterol, modificadas
NZ599830A (en) Novel kinase modulators
WO2010083441A3 (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2010079431A3 (en) Compounds for the prevention and treatment of cardiovascular disease
NZ615578A (en) Pyridopyrazine derivatives and their use
MX343931B (es) Tratamiento de la esclerosis lateral amiotrofica con el uso de celulas derivadas del cordon umbilical.
MX2014005209A (es) Un medicamento para tratar la enfermedad del ojo anterior que comprende rebamipida y un agente de retencion de lagrimas.
MX2010006039A (es) Compuestos antagonistas del acido ribonucleico para la modulacion de la expresion de la fosfoinositida-3-cinasa catalitica.
MY157237A (en) Azetidinone compounds and medical use thereof
BR112012013710A2 (pt) processos para a preparação de deferasirox e polimorfos de deferasirox.
WO2010102154A3 (en) Biaryl oxyacetic acid compounds
WO2013078376A3 (en) Isoxazole treatments for diabetes
CO6630197A2 (es) Nuevos procesos
MX2014003883A (es) Inhibidores de monoacilglicerol lipasa para el tratamiento de enfermedades metabolicas y transtornos relacionados.
MX2012007080A (es) [4[4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(1h-pirrolo-pi ri-din-il)-metanonas y sintesis de las mismas.
WO2007124005A3 (en) Methods for treating bone associated diseases by the use of methionine aminopeptidase-2 inhibitors

Legal Events

Date Code Title Description
FG Grant or registration